On Tuesday, DeVry Education Group Inc (NYSE:DV)’s shares declined -0.99% to $29.98.
DeVry Education Group Inc. (DV designated James D. White to fill a vacancy created by an enhance in the size of the Board from eight to nine members. The Board has not yet determined the committees of the Board to which Mr. White will be named.
Mr. White will take part in the cash and equity compensation programs offered to and upon the same terms as other non-employee directors, but with respect to service until DeVry Group’s next annual meeting of shareholders, will receive cash compensation on a pro-rated basis and will not receive an equity grant. These cash and equity compensation programs are more fully described under “2014 Director Compensation” in our Proxy Statement on Plan 14A filed with the Securities and Exchange Commission on October 8, 2014, which is incorporated in this Item 5.02 by reference.
DeVry Education Group Inc. provides educational services worldwide. It operates in three segments: Medical and Healthcare; International and Professional Educational; and Business, Technology and Administration. The Medical and Healthcare segment operates American University of the Caribbean School of Medicine, Ross University School of Medicine, Ross University School of Veterinary Medicine, Chamberlain College of Nursing, and Carrington College.
Google Inc (NASDAQ:GOOG)’s shares dropped -0.19% to $520.51.
Google Inc (GOOG) ‘s been systematically rolling out high frame rate (HFR) video — that’s 60 frames per second — across its YouTube ecosystem for a couple of months now. HFR debuted on standard videos last October. It hit YT’s live streaming service in May and recently Google declared that the YouTube mobile app for both iOS and Android will now feature 60 FPS playback. Now you’ll be able to follow Far Cry 4 walkthroughs on your mobile device with the same silky smooth playback that you see on your TV.
Google Inc., a technology company, builds products and provides services to organize the information. The company offers Google Search, which provides information online; Google Now that offers information to users when they need it; AdWords, an auction-based advertising program; AdSense, which enables Websites that are part of the Google network to deliver ads; DoubleClick Ad Exchange, a marketplace for the trading display ad space; and other advertising platforms, such as AdExchange and AdMob.
At the end of Tuesday’s trade, Galena Biopharma Inc (NASDAQ:GALE)‘s shares surged 2.41% to $1.70.
Galena Biopharma Inc (GALE) a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, recently declared that data from the Company’s Phase 2 clinical trial of GALE-401 was presented at the European Hematology Association 20th Congress in Vienna, Austria. The GALE-401 Phase 2 pilot study is a single arm, open label, multi-center study evaluating the efficacy and safety of anagrelide controlled release in subjects with thrombocytosis secondary to essential thrombocythemia (ET) and other myeloproliferative neoplasms (MPNs).
The poster presentation, entitled, “Phase 2 Study of a Novel Controlled-Release Formulation of Anagrelide (GALE-401) in Subjects with Myeloproliferative Neoplasm (MPN)-Related Thrombocytosis,” was presented on Saturday, June 13, 2015. The Phase 2 study demonstrated that GALE-401 was well tolerated with primarily Grade 1 and 2 toxicities in 16 of the 18 subjects enrolled. The efficacy shown in the trial compares favorably to historical anagrelide immediate release (IR) response rates with the following platelet response: overall response rate (ORR) of 78% (14/18); complete response (CR) of 39% (7/18); partial response (PR) of 39% (7/18). The median time to response was 5 weeks (range, 3-10), and the median duration of response has not yet been reached. Based on the data, the investigators concluded that GALE-401 remains a viable potential treatment option for MPNs, and a randomized trial comparing GALE-401 as compared to anagrelide IR is warranted. Final data from the GALE-401 Phase 2 trial is predictable to be presented at the American Society of Hematology conference in December.
Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology therapeutics that address major unmet medical needs across cancer care. Its commercial products comprise Abstral, a sublingual tablet that is used for the administration of breakthrough pain in patients with cancer; and Zuplenz, an oral soluble film for use in the prevention of emetogenic chemotherapy-induced, radiotherapy-induced, and post-operative nausea and vomiting.
Babcock & Wilcox Co (NYSE:BWC), ended its Tuesday’s trading session with 0.37% gain, and closed at $32.80.
The Babcock & Wilcox Company (B&W) (BWC) is happy to declare the grand opening of the Solid Waste Authority (SWA) of Palm Beach County’s advanced waste-to-energy facility, the Palm Beach Renewable Energy Facility 2 (PBREF2).
The facility, owned by the SWA and located in West Palm Beach, Fla., was designed, manufactured and constructed by a consortium of Babcock & Wilcox Power Generation Group, Inc. (B&W PGG) and KBR, Inc. It is the cleanest and most-advanced power plant of its kind in North America. The SWA and the consortium celebrated the facility’s grand opening with a ribbon cutting ceremony on Saturday, June 27.
B&W PGG designed and manufactured the plant’s three mass-burn, waste-to-energy boilers, capable of generating up to 95 megawatts of electricity, and its environmental control system. The plant features DynaGrate® air-cooled and water-cooled combustion grates designed by B&W Vølund and will be operated under a 20 year agreement by B&W PGG’s partner, Palm Beach Resource Recovery Corporation, which has operated the adjacent PBREF 1 since 1989.
The Babcock & Wilcox Company operates as a specialty constructor of nuclear components for customers in the power and other steam-using industries. The company operates through five segments: Power Generation, Nuclear Operations, Technical Services, Nuclear Energy, and mPower. The Power Generation segment provides fossil and renewable power generation equipment for capital projects with boiler products and environmental systems.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
